Aripiprazole: In Adolescents with Schizophrenia

Authors: Sanford, Mark; Keating, Gillian M.

Source: Pediatric Drugs, Volume 9, Number 6, 2007 , pp. 419-423(5)

Buy & download fulltext article:

Price: $62.95 plus tax (Refund Policy)

Abstract:

▴ Aripiprazole is a novel atypical antipsychotic that is approved in the US for use in adolescents with schizophrenia.

▴ In adolescents with schizophrenia, oral aripiprazole 10 or 30 mg/day lead to significantly greater reductions than placebo in the Positive and Negative Syndrome Scale (PANSS) total score from baseline to 6 weeks, according to findings from a randomized, double-blind, multicenter trial (n = 302).

▴ In addition, aripiprazole 10 or 30 mg/day recipients had significantly greater improvements in the PANSS positive subscale and Clinical Global Impression-Severity and -Improvement scale scores than placebo recipients, and a significantly greater improvement in the PANSS negative subscale score was seen with aripiprazole 10 mg/day than with placebo.

▴ Aripiprazole was generally well tolerated in adolescents with schizophrenia, with most adverse events being of mild to moderate severity. Clinically significant weight gain (≥7% as defined by the US FDA) occurred in 4.0% of aripiprazole 10 mg/day recipients, 5.2% of aripiprazole 30 mg/day recipients, and 1% of placebo recipients. The mean weight change was significantly different in aripiprazole and placebo recipients (0, +0.2, and −0.8kg in aripiprazole 10 mg/day, aripiprazole 30 mg/day, and placebo recipients, respectively).

Keywords: Adis Drug Profiles; Aripiprazole; Aripiprazole; Aripiprazole; Aripiprazole; Schizophrenia

Document Type: Research article

Affiliations: 1: Wolters Kluwer Health | Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania, USA

Publication date: 2007-01-01